NCT00030147View on ClinicalTrials.gov

Raloxifene and Rimostil for Perimenopause-Related Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Perimenopausal DepressionDepression
Interventions
DRUG

Raloxifene

60 mg a day orally administered

DRUG

Rimostil

1000 mg twice a day administered orally

DRUG

Transdermal Estradiol

100 microgram per day transdermal estradiol

DRUG

Placebo skin patch and placebo tablets

matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH

NCT00030147 - Raloxifene and Rimostil for Perimenopause-Related Depression | Biotech Hunter | Biotech Hunter